Stock Worth Mentioning: What’s in Asterias Biotherapeutics Inc After Today’s Big Decline?

Stock Worth Mentioning: What's in Asterias Biotherapeutics Inc After Today's Big Decline?

The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) is a huge mover today! About 236,664 shares traded hands or 25.13% up from the average. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 5.70% since April 27, 2016 and is uptrending. It has outperformed by 0.47% the S&P500.
The move comes after 6 months negative chart setup for the $190.69 million company. It was reported on Nov, 30 by Barchart.com. We have $3.82 PT which if reached, will make NYSEMKT:AST worth $17.16 million less.

Analysts await Asterias Biotherapeutics Inc (NYSEMKT:AST) to report earnings on April, 4. They expect $-0.17 earnings per share, up 19.05% or $0.04 from last year’s $-0.21 per share. After $-0.15 actual earnings per share reported by Asterias Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.

Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage

Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. The rating was initiated by FBR Capital on Thursday, November 19 with “Outperform”. The rating was initiated by Chardan Capital Markets with “Buy” on Monday, May 23. The rating was maintained by MLV with “Buy” on Tuesday, August 11.

According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”

More notable recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Prnewswire.com which released: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” on March 31, 2016, also Prnewswire.com with their article: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” published on September 14, 2016, Prnewswire.com published: “Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA …” on February 24, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) were released by: Prnewswire.com and their article: “Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics” published on November 17, 2016 as well as Prnewswire.com‘s news article titled: “Asterias Biotherapeutics Announces Intention to Distribute 3.15 Million …” with publication date: February 17, 2016.

AST Company Profile

Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment